COMMUNIQUÉS West-GlobeNewswire
-
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
02/02/2026 -
Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence
02/02/2026 -
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
02/02/2026 -
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
02/02/2026 -
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
02/02/2026 -
DLH to Announce Fiscal 2026 First Quarter Financial Results
02/02/2026 -
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
02/02/2026 -
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
02/02/2026 -
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
02/02/2026 -
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
02/02/2026 -
Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3
02/02/2026 -
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02/02/2026 -
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02/02/2026 -
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
02/02/2026 -
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
02/02/2026 -
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
02/02/2026 -
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas)
02/02/2026 -
Arctic Vision Announces Deal to Integrate MDCO Technology’s Ophthalmic Device Business to Form a Global Drug–Device Innovation Platform
02/02/2026 -
Every Smile Is Special: Sparkling Charms Dental Studio Highlights Sensory-Friendly Pediatric Dental Program for Children With Special Needs in Baltimore
02/02/2026
Pages